Pomegra
UK medtech Strolll combines Innovate UK grants and an IW Capital-led investor round to bring bedside augmented reality neurorehabilitation to acute stroke wards for the first time.
Key Takeaways
- Strolll secured a €4.18M Innovate UK innovation loan plus an €813K GCIP award, totaling €5M in public funding.
- IW Capital leads an additional investor round alongside Cleveland Clinic and Future Planet Capital Regional.
- Proceeds fund StrolllAcute, an AR rehabilitation system designed for bed-bound patients, and StrolllAssessment, an AI-driven neuromotor evaluation platform.
Lead
Strolll, the Stafford-based AR neurorehabilitation company, announced in September 2026 that it has secured €5 million in Innovate UK funding - structured as a €4.18 million innovation loan and an €813,200 Growth Catalyst Investor Partnerships award - alongside a separate equity round led by IW Capital, with Cleveland Clinic and Future Planet Capital Regional also participating. The combined capital will push two new products toward clinical deployment, including StrolllAcute, the company's first system built specifically for patients who cannot yet leave hospital beds.
What Does StrolllAcute Actually Do?
StrolllAcute delivers augmented reality therapy directly at the bedside, enabling stroke patients in acute care to begin neuromotor rehabilitation during the earliest, most neuroplastically receptive window - without requiring ward staff to change existing workflows or take on extra burden. That last constraint is not incidental. Acute wards are staff-constrained environments; any tool that adds friction does not get used. The product sits at the intersection of clinical urgency and operational reality in a way that earlier AR rehabilitation tools, typically aimed at ambulatory or outpatient settings, have not addressed.
Strolll's existing platform, which runs on off-the-shelf AR glasses, has already demonstrated in clinical trials that clinicians can deliver up to seven times more treatments while using 67% less staff time. StrolllAcute extends that efficiency argument to the highest-acuity setting in stroke care.
Why Does the Timing of Stroke Rehab Matter?
The window immediately following a stroke is when the brain retains the highest capacity to rewire damaged neural pathways - a process called neuroplasticity. Conventional acute ward environments rarely support intensive motor rehabilitation during this period because patients are immobile, understaffed wards are stretched, and existing rehabilitation tools are designed for patients who can already stand or walk. The gap between stroke onset and the start of meaningful motor therapy can span days, compounding long-term disability outcomes.
StrolllAcute's bet is that closing that gap - even partially - changes recovery trajectories at population scale. Stroke affects roughly 100,000 people in the UK each year, and the costs of long-term disability following inadequate early rehabilitation run into the billions annually for the NHS.
Funding Structure and What It Signals
The Innovate UK innovation loan, at €4.18 million, will underwrite StrolllAssessment - a parallel product that pairs AI with a fully equipped biomechanics lab environment to validate digital neuromotor assessments faster and at greater scale. The smaller GCIP award, combined with over €1.16 million from the IW Capital-led investor round, is earmarked specifically for StrolllAcute's commercial rollout.
IW Capital's continued involvement is notable. The firm led Strolll's €12.2 million Series A in March 2025, which at the time represented one of the larger medtech raises in the UK Midlands. A follow-on from the same lead at a smaller ticket - structured partly as public debt rather than pure equity - suggests the parties are pacing capital deployment to product readiness milestones rather than staging a fresh push for valuation. Cleveland Clinic's presence in the investor syndicate doubles as a strategic signal: the US hospital system began its partnership with Strolll in 2024 and represents a credible entry point into the American market for any future commercial expansion.
Strategic Context
Founded in 2018 by CEO Jorgen Ellis, Strolll has built its core platform around software-as-a-medical-device delivered via consumer AR glasses - a model that keeps hardware costs low and upgrade cycles short. The company has positioned itself at the more clinically rigorous end of the digital therapeutics spectrum, pursuing regulatory pathways and hospital partnerships rather than consumer distribution.
The dual-product strategy - one tool for assessment, one for acute therapy - allows Strolll to capture multiple points in the care pathway rather than competing only at the rehabilitation stage. StrolllAssessment addresses measurement and validation, areas where neuromotor science has historically lacked scalable, standardized tools. That positions the company to embed in clinical workflows earlier and deeper than a standalone therapy product would allow.
Outlook
Strolll enters the second half of 2026 with a clearer product architecture than most medtech companies at its stage. The Innovate UK loan validates the scientific underpinning of StrolllAssessment; the GCIP-plus-equity structure gives StrolllAcute a defined commercial runway. The harder work - NHS procurement timelines, regulatory clearance in new markets, and the perennial challenge of getting clinician behavior to change at scale - begins now. Cleveland Clinic's participation raises the question of US market entry, but no timeline has been confirmed. For now, the company's near-term credibility rests on whether bedside AR in acute wards demonstrates measurable patient outcomes outside of controlled trial conditions.
